For patients with metastatic melanoma, neutrophil/lymphocyte ratio before initiating ipilimumab treatment is an independent prognostic indicator of poor survival, according to a study published online Sept. 6 in the British Journal of Dermatology.
Publications
Immune Irregularities May Increase Melanoma Risk Among Certain Non-Hodgkin’s Lymphoma Survivors
A collaborative team of interdisciplinary researchers led by Clara J.K. Lam, MPH, a predoctoral fellow in the Radiation Epidemiology Branch of the National Cancer Institute (NCI) and PhD student in cancer epidemiology at the George Washington University School of Public Health and Health Services, recently revealed study findings suggesting that immune irregularities may contribute to the high rates of melanoma observed in patients with non-hodgkins lymphoma (NHL) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). The findings from the study entitled, “Risk Factors for Melanoma Among Survivors of Non-Hodgkin Lymphoma,” were published in the latest edition of the Journal of Clinical Oncology the official journal of the American Society for Clinical Oncology.
Identifying protein that may predict response to PD-1 immunotherapy for melanoma
Mayo Clinic researchers have identified a protein marker whose frequency may predict patient response to PD-1 blockade immunotherapy for melanoma. An abstract of their findings was presented today at the American Association for Cancer Research International Cancer Immunotherapy Conference in New York City.
Melanoma New Zealand delighted with KEYTRUDA registration
Melanoma New Zealand is delighted that anti-PD1 immunotherapy KEYTRUDA® (pembrolizumab) has been approved by Medsafe and is now a registered medicine in New Zealand.
Chief Executive Officer of Melanoma New Zealand, Linda Flay, says: “This is an important step for New Zealanders. Along with Australia, we have the highest incidence of melanoma in the world and 30 percent of cases occur in people under the age of 50.